Advertisement
Neha420

Europe Prothrombin Complex Concentrate Market Share, Growth Insight, Size and Forecast To 2027

Aug 12th, 2021
104
0
Never
Not a member of Pastebin yet? Sign Up, it unlocks many cool features!
text 6.96 KB | None | 0 0
  1. The Europe prothrombin complex concentrate market size is projected to reach USD 398.9 million by 2027, exhibiting a CAGR of 10.9% during the forecast period. The substantial advantages offered by prothrombin complex concentrate (PCC) will be the primary driving force behind this market’s growth, forecasts Fortune Business Insights™ in its report, titled “Europe Prothrombin Complex Concentrate Market Size, Share & Covid-19 Impact Analysis, By Product (4-factor PCC and 3-factor PCC), By Application (Acquired Coagulation Deficiency and Congenital Coagulation Deficiency and By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics, and Others), 2020-2027”.
  2.  
  3. PCC (factor IX complex) is a medication comprising blood clotting factors II, IX, and X, indicated for treating bleeding in patients with hemophilia B. This line of treatment offers a host of benefits, especially when compared to Fresh Frozen Plasma (FFP), a leading anticoagulation-reversal therapy.
  4.  
  5. For More Information in the Analysis of Report: https://www.fortunebusinessinsights.com/europe-prothrombin-complex-concentrate-pcc-market-104721
  6.  
  7. List of Key Companies Profiled in the Europe Prothrombin Complex Concentrate Market Report:
  8.  
  9. Takeda Pharmaceutical Company Limited
  10. Kedrion S.p.A
  11. Grifols, S.A.
  12. Sanquin
  13. Octapharma AG
  14. CSL Limited
  15. Increasing Geriatric Populations across Europe to Create Market Opportunities
  16.  
  17. An emerging factor driving the Europe prothrombin complex concentrate market growth is the rapidly aging populations across the continent. According to the latest data released by the UN’s Population Division, nearly 25% of Europe’s people are aged 60 years and above. Moreover, the European Commission (EC) predicts that the proportion of people above the age of 80 in the EU-27 will increase from 5.8% to 14.6% between 2019 and 2100. Older persons are at a heightened risk of acute liver injury and also face increased susceptibility to the fibrotic response. Prothrombin complex concentrate has proven to be highly effective in treating patients with liver disease as they frequently develop coagulopathy.
  18.  
  19. A study conducted in 2019 by researchers from the Royal Free Hospital, London and University College London found that PCC therapy was effective in improving coagulation test results in patients with liver disease, without any excess thrombotic events. Such research studies proving the efficacy of PCC treatments, complemented by a rising number of older persons, will bolster the prospects of this market in Europe.
  20.  
  21. Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/europe-prothrombin-complex-concentrate-pcc-market-104721
  22.  
  23. Germany to Spearhead the Europe PCC Market; the UK to Display Promising Growth
  24.  
  25. Germany is anticipated to headline the Europe prothrombin complex concentrate market share during the forecast period owing to a large pool of patients suffering from congenital factor IX deficiency. In 2019, the country’s market size stood at USD 46.0 million. In the UK, on the other hand, the rising incidence of hemophilia B will be the principal growth driver for the country’s market. Further, the market in Scandinavia will be propelled by the strong presence and operations of CSL Behring in the region and the wide popularity of its prothrombin complex concentrate brand, Confidex.
  26.  
  27. New Product Introductions to Charge up Market Competition
  28.  
  29. The competitive dynamics of the Europe prothrombin complex concentrate market are dictated by the presence of a limited number of key players, mainly pharmaceutical giants in Europe. These companies are concentrating on releasing new PCC products to capture the growing regional demand for efficient solutions to manage bleeding disorders.
  30.  
  31. Table of Content:
  32.  
  33. Introduction
  34. Research Scope
  35. Market Segmentation
  36. Research Methodology
  37. Definitions and Assumptions
  38. Executive Summary
  39. Market Dynamics
  40. Market Drivers
  41. Market Restraints
  42. Market Opportunities
  43. Key Insights
  44. Epidemiology of Coagulation Factor Deficiency – For Key Countries
  45. Recent Industry Developments – Partnerships, Mergers & Acquisitions
  46. Regulatory Scenario – For Key Countries
  47. Analysis in Relation to Alternatives to PCC
  48. PCC Market: Reimbursement Scenario & Key Industry Trends
  49. Impact of COVID-19 on Europe PCC Market
  50. Europe Prothrombin Complex Concentrate Market Analysis, Insights and Forecast, 2016-2027
  51. Key Findings / Summary
  52. Market Analysis, Insights and Forecast – By Product - By Value (US$, Mn)
  53. 3-factor PCC
  54. 4-factor PCC
  55. Market Analysis, Insights and Forecast – By Application-By Value (US$, Mn)
  56. Acquired Coagulation Factor Deficiency
  57. Congenital Coagulation Factor Deficiency
  58. Market Analysis, Insights and Forecast – By End User - By Value (US$, Mn)
  59. Hospitals
  60. Ambulatory Surgical Centers
  61. Others
  62. Market Analysis, Insights and Forecast – By Country/Sub-region
  63. U.K.
  64. Germany
  65. France
  66. Italy
  67. Spain
  68. Scandinavia
  69. Rest of Europe
  70. U.K. Prothrombin Complex Concentrate Market Analysis, Insights and Forecast, 2016-2027
  71. Key Findings / Summary
  72. Market Analysis, Insights and Forecast – By Product - By Value (US$, Mn)
  73. 3-factor PCC
  74. 4-factor PCC
  75. Market Analysis, Insights and Forecast – By Application-By Value (US$, Mn)
  76. Acquired Coagulation Factor Deficiency
  77. Congenital Coagulation Factor Deficiency
  78. Market Analysis, Insights and Forecast – By End User - By Value (US$, Mn)
  79. Hospitals
  80. Ambulatory Surgical Centers
  81. Others
  82. TOC Continued….!
  83.  
  84. Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/europe-prothrombin-complex-concentrate-pcc-market-104721
  85.  
  86. About Us:
  87.  
  88. Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
  89.  
  90. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
  91.  
  92. At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
  93.  
  94. Contact Us:
  95.  
  96. Fortune Business Insights™ Pvt. Ltd.
  97. 308, Supreme Headquarters,
  98. Survey No. 36, Baner,
  99. Pune-Bangalore Highway,
  100. Pune - 411045, Maharashtra, India.
  101.  
  102. Phone:
  103. US :+1 424 253 0390
  104. UK : +44 2071 939123
  105. APAC : +91 744 740 1245
  106. Email: sales@fortunebusinessinsights.com
  107. Fortune Business Insights™
  108. LinkedIn | Twitter | Blogs
Advertisement
Add Comment
Please, Sign In to add comment
Advertisement